Skip to main content
Premium Trial:

Request an Annual Quote

UCLA Installs HistoRx's Imaging-Analysis Tool in Biomarker Lab

NEW YORK (GenomeWeb News) — Biomarker profiling company HistoRx said yesterday that the University of California at Los Angeles has installed its image-analysis tool.
 
The New Haven, Conn.-based company said UCLA will use the PM-2000 system at its Biomarker Innovation Laboratory to develop in situ diagnostic assays.
 
Financial terms of the deal were not disclosed.
 
The PM-2000 employs HistoRx’s automated quantitative analysis technology to measure protein biomarkers in tissue and in tissue microarrays.
The company said the technology was developed at Yale University’s medical school and is being used through a corporate/academic research program at nine cancer and pathology research centers.
 
Yale researcher David Rimm, who developed the quantitative analysis technology, co-founded HistoRx and also serves as the company’s chief of medical affairs.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.